drugset
drugset / Trial / NCT00307177

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

NCT00307177 ↗

Phase 2 Completed 28 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this research is to compare reactions and antibody responses following receipt of different doses of the experimental influenza vaccine or standard influenza vaccine.

Timeline

Start
2004-08
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza Virus Vaccine Vaccine 15 ug Intramuscular
Subject Trivalent Baculovirus-expressed Influenza HA vaccine Vaccine 15 ug Intramuscular
Subject Trivalent Baculovirus-expressed Influenza HA vaccine Vaccine 45 ug Intramuscular
Subject Trivalent Baculovirus-expressed Influenza HA vaccine Vaccine 135 ug Intramuscular

Indications

influenza